blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3405212

EP3405212 - CANCER VACCINES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.05.2021
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  30.01.2020
FormerExamination is in progress
Status updated on  07.05.2019
FormerRequest for examination was made
Status updated on  26.10.2018
FormerThe international publication has been made
Status updated on  28.07.2017
Formerunknown
Status updated on  13.02.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
[2018/48]
Inventor(s)01 / BINDER, Joseph John
12282 Cornwallis Square
San Diego, CA 92128 / US
02 / CHO, Helen Kim
4127 Twilight Ridge
San Diego, CA 92130 / US
03 / COCKLE, Paul Jason
126 Redwood Road
San Anselmo, CA 94960 / US
04 / FALCONER, Derek John
4651 Torrey Circle
Apt. K302
San Diego, CA 92130 / US
05 / GURU, Siradanahalli
10515 Abalone Landing Terrace
San Diego, CA 92130 / US
06 / JOOSS, Karin Ute
3712 Garden Lane
San Diego, CA 92106 / US
07 / MARTINIC, Marianne Marcela Andrea
8623 Via Mallorca
Unit C
La Jolla, CA 92037 / US
08 / WILLS, Kenneth Nelson
7806 Via Opuntia
Carlsbad, CA 92009 / US
 [2018/48]
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2018/48]
Application number, filing date17702951.916.01.2017
[2018/48]
WO2017IB50229
Priority number, dateUS201662280636P19.01.2016         Original published format: US 201662280636 P
US201662419190P08.11.2016         Original published format: US 201662419190 P
[2018/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017125844
Date:27.07.2017
Language:EN
[2017/30]
Type: A1 Application with search report 
No.:EP3405212
Date:28.11.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 27.07.2017 takes the place of the publication of the European patent application.
[2018/48]
Type: B1 Patent specification 
No.:EP3405212
Date:08.07.2020
Language:EN
[2020/28]
Search report(s)International search report - published on:EP27.07.2017
ClassificationIPC:A61K39/00
[2018/48]
CPC:
A61K39/0011 (EP,IL,RU,US); A61K39/00 (EP,IL,RU,US); A61K40/4257 (KR);
A61K31/711 (EP,IL,US); A61K39/001157 (EP,IL,RU,US); A61K39/00117 (EP,IL,RU,US);
A61K45/06 (KR); A61K48/005 (IL,US); A61P1/18 (EP);
A61P15/00 (EP); A61P35/00 (EP,IL,KR); A61P37/04 (EP);
A61P43/00 (EP); C07K14/4727 (KR); C12N15/62 (EP,IL,US);
A61K2039/53 (EP,IL,KR,US); A61K2039/57 (IL,US); A61K2039/575 (IL,KR,US);
A61K2039/585 (IL,KR,US); A61K2039/70 (IL,KR,US); A61K2039/812 (KR);
A61K2039/852 (KR); A61K2039/892 (KR); A61K2121/00 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/48]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:IMPFSTOFFE GEGEN KREBS[2020/04]
English:CANCER VACCINES[2018/48]
French:VACCINS CONTRE LE CANCER[2020/04]
Former [2018/48]KREBSIMPFSTOFFE
Former [2018/48]VACCINS ANTICANCÉREUX
Entry into regional phase20.08.2018National basic fee paid 
20.08.2018Designation fee(s) paid 
20.08.2018Examination fee paid 
Examination procedure30.07.2018Amendment by applicant (claims and/or description)
20.08.2018Examination requested  [2018/48]
20.08.2018Date on which the examining division has become responsible
10.05.2019Despatch of a communication from the examining division (Time limit: M06)
15.11.2019Reply to a communication from the examining division
31.01.2020Communication of intention to grant the patent
20.05.2020Fee for grant paid
20.05.2020Fee for publishing/printing paid
20.05.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20175571.7  / EP3733201
Opposition(s)09.04.2021No opposition filed within time limit [2021/24]
Fees paidRenewal fee
31.01.2019Renewal fee patent year 03
31.01.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL08.07.2020
CY08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
RS08.07.2020
SM08.07.2020
[2024/42]
Former [2024/22]AL08.07.2020
CY08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
RS08.07.2020
SM08.07.2020
Former [2023/30]AL08.07.2020
CY08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
RS08.07.2020
SM08.07.2020
Former [2021/40]AL08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
RS08.07.2020
SM08.07.2020
Former [2021/25]AL08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
RS08.07.2020
SM08.07.2020
Former [2021/22]EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
RS08.07.2020
SM08.07.2020
Former [2021/12]HR08.07.2020
LT08.07.2020
LV08.07.2020
RS08.07.2020
Former [2021/07]LT08.07.2020
Cited inInternational search[I]WO2013025972  (GLOBEIMMUNE INC [US], et al);
by applicantEP0187702
 US4603112
 US4769330
 WO8901973
 WO9011092
 WO9014837
 US5017487
 WO9115501
 US5091309
 US5217879
 US5219740
 US5283185
 US5288641
 WO9526356
 US5527928
 EP0735898
 US5580859
 US5589466
 US5591624
 EP0761231
 US5688688
 US5716613
 US5716826
 US5716832
 EP0835318
 US5789245
 WO9837919
 WO9840100
 US5814482
 US5817491
 WO9852581
 US5843723
 WO9855495
 US5851529
 WO9857659
 WO9911241
 WO9944636
 WO9952549
 WO0056358
 WO0062800
 WO0114424
 WO0121207
 WO0121152
 WO03041070
 US6682736
 WO2005071093
 US7387882
 WO2010005958
 WO2010086189
 US8088803
 WO2015063647
 WO2015173764
 US2015329525
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.